Sandoz And Polpharma Strike Global Deal For Natalizumab
Polpharma and Sandoz have stuck a global licensing deal that gives the Novartis subsidiary rights to market the Polish firm’s biosimilar natalizumab rival to Biogen’s Tysabri.
You may also be interested in...
Poland’s Polpharma SA has absorbed subsidiaries Polpharma BH and Medana Pharma as part of the group’s efforts to simplify management structures and processes and increase operational efficiency.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.
As it gears up to begin production at its new clinical and commercial manufacturing site in Warsaw, Polpharma Biologics has announced a new logo and corporate message to mark a year of “significant growth.”